학술논문
Maraviroc Intensification of cART in Patients with Suboptimal Immunological Recovery: A 48-Week, Placebo-Controlled Randomized Trial.
Document Type
article
Author
Steven F L van Lelyveld; Julia Drylewicz; Maaike Krikke; Ellen M Veel; Sigrid A Otto; Clemens Richter; Robin Soetekouw; Jan M Prins; Kees Brinkman; Jan Willem Mulder; Frank Kroon; Ananja Middel; Jori Symons; Annemarie M J Wensing; Monique Nijhuis; José A M Borghans; Kiki Tesselaar; Andy I M Hoepelman; MIRS study group
Source
PLoS ONE, Vol 10, Iss 7, p e0132430 (2015)
Subject
Language
English
ISSN
1932-6203
Abstract
The immunomodulatory effects of the CCR5-antagonist maraviroc might be beneficial in patients with a suboptimal immunological response, but results of different cART (combination antiretroviral therapy) intensification studies are conflicting. Therefore, we performed a 48-week placebo-controlled trial to determine the effect of maraviroc intensification on CD4+ T-cell counts and immune activation in these patients.Double-blind, placebo-controlled, randomized trial.Major inclusion criteria were 1. CD4+ T-cell count